当前位置: 首页 >> 检索结果
701. A functional polymorphism in the epidermal growth factor gene is associated with risk for hepatocellular carcinoma.
作者: Barham K Abu Dayyeh.;May Yang.;Bryan C Fuchs.;Daniel L Karl.;Suguru Yamada.;John J Sninsky.;Thomas R O'Brien.;Jules L Dienstag.;Kenneth K Tanabe.;Raymond T Chung.; .
来源: Gastroenterology. 2011年141卷1期141-9页
A single nucleotide polymorphism 61*G (rs4444903) in the epidermal growth factor (EGF) gene has been associated, in 2 case-control studies, with hepatocellular carcinoma (HCC). We tested associations between demographic, clinical, and genetic data and development of HCC, and developed a simple predictive model in a cohort of patients with chronic hepatitis C and advanced fibrosis.
702. Enteral and parenteral nutrition in the conservative treatment of pancreatic fistula: a randomized clinical trial.
作者: Stanislaw Klek.;Marek Sierzega.;Lukasz Turczynowski.;Piotr Szybinski.;Kinga Szczepanek.;Jan Kulig.
来源: Gastroenterology. 2011年141卷1期157-63, 163.e1页
Postoperative pancreatic fistula is the most common and potentially life-threatening complication after pancreatic surgery. Although nutritional support is a key component of conservative therapy in such cases, there have been no well-designed clinical trials substantiating the superiority of either total parenteral nutrition or enteral nutrition. This study was conducted to compare the efficacy and safety of both routes of nutritional intervention.
703. High-dose pegylated interferon-α and ribavirin in nonresponder hepatitis C patients and relationship with IL-28B genotype (SYREN trial).
作者: Stéphane Chevaliez.;Christophe Hézode.;Alexandre Soulier.;Bruno Costes.;Magali Bouvier-Alias.;Stéphanie Rouanet.;Juliette Foucher.;Jean-Pierre Bronowicki.;Albert Tran.;Isabelle Rosa.;Philippe Mathurin.;Laurent Alric.;Vincent Leroy.;Patrice Couzigou.;Ariane Mallat.;Mariem Charaf-Eddine.;Gérard Babany.;Jean-Michel Pawlotsky.
来源: Gastroenterology. 2011年141卷1期119-27页
In patients with chronic hepatitis C who failed to respond to standard therapy, high-dose pegylated interferon (IFN)-α and/or ribavirin could induce a stronger antiviral response and prevent treatment failure and HCV resistance when combined with direct-acting antivirals. The influence of genetic determinants in this context remains unknown.
704. Maintenance therapy with peginterferon alfa-2b does not prevent hepatocellular carcinoma in cirrhotic patients with chronic hepatitis C.
作者: Jordi Bruix.;Thierry Poynard.;Massimo Colombo.;Eugene Schiff.;Kelly Burak.;Elizabeth J L Heathcote.;Thomas Berg.;Jorge-Luis Poo.;Carlos Brandao Mello.;Rainer Guenther.;Claus Niederau.;Ruben Terg.;Pierre Bedossa.;Navdeep Boparai.;Louis H Griffel.;Margaret Burroughs.;Clifford A Brass.;Janice K Albrecht.; .
来源: Gastroenterology. 2011年140卷7期1990-9页
Several studies have reported that low doses of interferon can delay the development of hepatocellular carcinoma (HCC) and progression of chronic hepatitis C. We investigated the incidence of clinical events among participants of the Evaluation of PegIntron in Control of Hepatitis C Cirrhosis (EPIC)3 program.
705. Endoscopic trimodal imaging detects colonic neoplasia as well as standard video endoscopy.
作者: Teaco Kuiper.;Frank J C van den Broek.;Anton H Naber.;Ellert J van Soest.;Pieter Scholten.;Rosalie Ch Mallant-Hent.;Jan van den Brande.;Jeroen M Jansen.;Arnoud H A M van Oijen.;Willem A Marsman.;Jacques J G H M Bergman.;Paul Fockens.;Evelien Dekker.
来源: Gastroenterology. 2011年140卷7期1887-94页
Endoscopic trimodal imaging (ETMI) is a novel endoscopic technique that combines high-resolution endoscopy (HRE), autofluorescence imaging (AFI), and narrow-band imaging (NBI) that has only been studied in academic settings. We performed a randomized, controlled trial in a nonacademic setting to compare ETMI with standard video endoscopy (SVE) in the detection and differentiation of colorectal lesions.
706. Acetaminophen-cysteine adducts during therapeutic dosing and following overdose.
作者: Kennon J Heard.;Jody L Green.;Laura P James.;Bryan S Judge.;Liza Zolot.;Sean Rhyee.;Richard C Dart.
来源: BMC Gastroenterol. 2011年11卷20页
Acetaminophen-cysteine adducts (APAP-CYS) are a specific biomarker of acetaminophen exposure. APAP-CYS concentrations have been described in the setting of acute overdose, and a concentration >1.1 nmol/ml has been suggested as a marker of hepatic injury from acetaminophen overdose in patients with an ALT >1000 IU/L. However, the concentrations of APAP-CYS during therapeutic dosing, in cases of acetaminophen toxicity from repeated dosing and in cases of hepatic injury from non-acetaminophen hepatotoxins have not been well characterized. The objective of this study is to describe APAP-CYS concentrations in these clinical settings as well as to further characterize the concentrations observed following acetaminophen overdose.
707. Coffee consumption is associated with response to peginterferon and ribavirin therapy in patients with chronic hepatitis C.
作者: Neal D Freedman.;Teresa M Curto.;Karen L Lindsay.;Elizabeth C Wright.;Rashmi Sinha.;James E Everhart.; .
来源: Gastroenterology. 2011年140卷7期1961-9页
High-level coffee consumption has been associated with reduced progression of pre-existing liver diseases and lower risk of hepatocellular carcinoma. However, its relationship with therapy for hepatitis C virus infection has not been evaluated.
708. Effects of omeprazole on symptoms and quality of life in Japanese patients with reflux esophagitis: final results of OMAREE, a large-scale clinical experience investigation.
For patients with reflux esophagitis (RE), endoscopic findings alone (without the frequency and severity of symptoms) may not fully reflect the associated impact on health-related quality of life (QOL). There is not enough data about symptoms and QOL of Japanese patients with RE. The present study therefore investigated the epidemiological characteristics of such patients, and evaluated the efficacy and safety of omeprazole (and other gastrointestinal drugs, except proton pump inhibitors [PPIs]) in terms of improving patients' symptoms and QOL.
709. Iron levels in hepatocytes and portal tract cells predict progression and outcomes of patients with advanced chronic hepatitis C.
作者: Richard W Lambrecht.;Richard K Sterling.;Deepa Naishadham.;Anne M Stoddard.;Thomas Rogers.;Chihiro Morishima.;Timothy R Morgan.;Herbert L Bonkovsky.; .
来源: Gastroenterology. 2011年140卷5期1490-500.e3页
Iron may influence severity and progression of non-hemochromatotic liver diseases. Our aim was to assess the relationship of iron and HFE genetic variations to progression and outcomes in the HALT-C Trial and whether PegIFN therapy influenced iron variables.
710. An alerting system improves adherence to follow-up recommendations from colonoscopy examinations.
作者: Daniel A Leffler.;Naama Neeman.;James M Rabb.;Jacob Y Shin.;Bruce E Landon.;Kumar Pallav.;Z Myron Falchuk.;Mark D Aronson.
来源: Gastroenterology. 2011年140卷4期1166-1173.e1-3页
Systems are available to ensure that results of tests are communicated to patients. However, lack of adherence to recommended follow-up evaluation increases risk for adverse health outcomes and medical or legal issues. We tested the effectiveness of a novel follow-up system for patients due for surveillance colonoscopy examinations.
711. Esomeprazole with clopidogrel reduces peptic ulcer recurrence, compared with clopidogrel alone, in patients with atherosclerosis.
We performed a prospective, randomized, controlled study to compare the combination of esomeprazole and clopidogrel vs clopidogrel alone in preventing recurrent peptic ulcers in patients with atherosclerosis and a history of peptic ulcers. We also investigated the effects of esomeprazole on the antiplatelet action of clopidogrel.
712. Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C.
作者: Anna S Lok.;James E Everhart.;Elizabeth C Wright.;Adrian M Di Bisceglie.;Hae-Young Kim.;Richard K Sterling.;Gregory T Everson.;Karen L Lindsay.;William M Lee.;Herbert L Bonkovsky.;Jules L Dienstag.;Marc G Ghany.;Chihiro Morishima.;Timothy R Morgan.; .
来源: Gastroenterology. 2011年140卷3期840-9; quiz e12页
Interferon reportedly decreases the incidence of hepatocellular carcinoma (HCC) in patients with chronic hepatitis C. The Hepatitis C Antiviral Long-term Treatment against Cirrhosis (HALT-C) Trial showed that 4 years of maintenance therapy with pegylated interferon (peginterferon) does not reduce liver disease progression. We investigated whether peginterferon decreases the incidence of HCC in the HALT-C cohort over a longer posttreatment follow-up period.
713. Primary repair of colon injuries: clinical study of nonselective approach.
This study was designed to determine the role of primary repair and to investigate the possibility of expanding indications for primary repair of colon injuries using nonselective approach.
714. Management of irritable bowel syndrome in primary care: feasibility randomised controlled trial of mebeverine, methylcellulose, placebo and a patient self-management cognitive behavioural therapy website. (MIBS trial).
作者: Hazel A Everitt.;Rona E Moss-Morris.;Alice Sibelli.;Laura Tapp.;Nicholas S Coleman.;Lucy Yardley.;Peter W Smith.;Paul S Little.
来源: BMC Gastroenterol. 2010年10卷136页
IBS affects 10-22% of the UK population. Abdominal pain, bloating and altered bowel habit affect quality of life, social functioning and time off work. Current GP treatment relies on a positive diagnosis, reassurance, lifestyle advice and drug therapies, but many suffer ongoing symptoms.A recent Cochrane review highlighted the lack of research evidence for IBS drugs. Neither GPs, nor patients have good evidence to inform prescribing decisions. However, IBS drugs are widely used: In 2005 the NHS costs were nearly £10 million for mebeverine and over £8 million for fibre-based bulking agents. CBT and self-management can be helpful, but poor availability in the NHS restricts their use. We have developed a web-based CBT self-management programme, Regul8, based on an existing evidence based self-management manual and in partnership with patients. This could increase access with minimal increased costs.
715. Budesonide 9 mg is at least as effective as mesalamine 4.5 g in patients with mildly to moderately active Crohn's disease.
作者: Andreas Tromm.;Ivan Bunganič.;Eva Tomsová.;Zsolt Tulassay.;Milan Lukáš.;Jan Kykal.;Marian Bátovský.;Bohumil Fixa.;Libor Gabalec.;Rifaat Safadi.;Heinz-Jochen Kramm.;István Altorjay.;Hanns Löhr.;Ioannis Koutroubakis.;Simon Bar-Meir.;Davor Stimac.;Elke Schäffeler.;Christoph Glasmacher.;Karin Dilger.;Ralf Mohrbacher.;Roland Greinwald.; .
来源: Gastroenterology. 2011年140卷2期425-434.e1; quiz e13-4页
Comparative data on budesonide vs mesalamine for the treatment of mild-to-moderately active Crohn's disease (CD) are sparse. We assessed the efficacy and safety of each therapy in patients with mildly to moderately active CD.
716. The combination of ribavirin and peginterferon is superior to peginterferon and placebo for children and adolescents with chronic hepatitis C.
作者: Kathleen B Schwarz.;Regino P Gonzalez-Peralta.;Karen F Murray.;Jean P Molleston.;Barbara A Haber.;Maureen M Jonas.;Philip Rosenthal.;Parvathi Mohan.;William F Balistreri.;Michael R Narkewicz.;Lesley Smith.;Steven J Lobritto.;Stephen Rossi.;Alexandra Valsamakis.;Zachary Goodman.;Patricia R Robuck.;Bruce A Barton.; .
来源: Gastroenterology. 2011年140卷2期450-458.e1页
Although randomized trials of adults infected with hepatitis C virus (HCV) have shown that ribavirin increases the efficacy of pegylated interferon (PEG), such trials have not been performed in children. We conducted a randomized controlled trial of PEG and ribavirin, compared with PEG and placebo, in children 5 to 17 years old with chronic hepatitis C.
717. Telaprevir is effective given every 8 or 12 hours with ribavirin and peginterferon alfa-2a or -2b to patients with chronic hepatitis C.
作者: Patrick Marcellin.;Xavier Forns.;Tobias Goeser.;Peter Ferenci.;Frederik Nevens.;Giampiero Carosi.;Joost P Drenth.;Lawrence Serfaty.;Koen De Backer.;Rolf Van Heeswijk.;Donghan Luo.;Gaston Picchio.;Maria Beumont.
来源: Gastroenterology. 2011年140卷2期459-468.e1; quiz e14页
Recent studies have shown that 12 weeks of treatment with telaprevir, administered every 8 hours (q8h), combined with pegylated interferon (peginterferon) alfa-2a plus ribavirin significantly increased the rate of hepatitis C virus (HCV) eradication (sustained virologic response [SVR]) in patients infected with HCV genotype 1 compared with approved therapy. We investigated the efficacy, safety, tolerability, and pharmacokinetics of telaprevir given q8h or every 12 hours (q12 h) in combination with peginterferon alfa-2a or alfa-2b.
718. Endoscopic ultrasonography-guided ethanol lavage with paclitaxel injection treats patients with pancreatic cysts.
作者: Hyoung-Chul Oh.;Dong Wan Seo.;Tae Jun Song.;Sung-Hoon Moon.;Do Hyun Park.;Sang Soo Lee.;Sung Koo Lee.;Myung-Hwan Kim.;Jihun Kim.
来源: Gastroenterology. 2011年140卷1期172-9页
Endoscopic ultrasonography (EUS)-guided interventions have been used to treat patients with cystic lesions of the pancreas (CLPs). We used EUS to guide injection and lavage of ethanol, followed by injection of paclitaxel, into cysts, and investigated treatment response and predictors.
719. S-adenosyl methionine improves early viral responses and interferon-stimulated gene induction in hepatitis C nonresponders.
作者: Jordan J Feld.;Apurva A Modi.;Ramy El-Diwany.;Yaron Rotman.;Emmanuel Thomas.;Golo Ahlenstiel.;Rachel Titerence.;Christopher Koh.;Vera Cherepanov.;Theo Heller.;Marc G Ghany.;Yoon Park.;Jay H Hoofnagle.;T Jake Liang.
来源: Gastroenterology. 2011年140卷3期830-9页
Less than half of patients infected with hepatitis C virus (HCV) achieve sustained viral clearance after pegylated interferon (peginterferon) and ribavirin therapy. S-adenosyl methionine (SAMe) improves interferon signaling in cell culture. We assessed the effect of SAMe on the kinetics of the early antiviral response and interferon signaling in nonresponders to previous antiviral therapy and investigated the mechanisms involved.
720. Rifaximin improves driving simulator performance in a randomized trial of patients with minimal hepatic encephalopathy.
作者: Jasmohan S Bajaj.;Douglas M Heuman.;James B Wade.;Douglas P Gibson.;Kia Saeian.;Jacob A Wegelin.;Muhammad Hafeezullah.;Debulon E Bell.;Richard K Sterling.;R Todd Stravitz.;Michael Fuchs.;Velimir Luketic.;Arun J Sanyal.
来源: Gastroenterology. 2011年140卷2期478-487.e1页
Patients with cirrhosis and minimal hepatic encephalopathy (MHE) have driving difficulties but the effects of therapy on driving performance is unclear. We evaluated whether performance on a driving simulator improves in patients with MHE after treatment with rifaximin.
|